Valsts: Īrija
Valoda: angļu
Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)
Carprofen
Krka, d.d., Novo mesto
QM01AE91
Carprofen
20 mg/tablet
Tablet
POM: Prescription Only Medicine as defined in relevant national legislation
Dogs
carprofen
N.S.A.I.D.
Authorised
2014-05-02
Health Products Regulatory Authority 02 November 2018 CRN000YDN Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 20 mg tablets for dogs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE: Carprofen 20.00 mg EXCIPIENTS: Ferric oxide red (E172) 0.61 mg Ferric oxide black (E172) 0.38 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. Round, dark brown, marbled tablets with visible darker spots, one-side scored and bevel-edged. The tablet can be divided into equal parts. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Reduction of inflammation and pain caused by musculoskeletal disorders and degenerative joint disease. As a follow up to parenteral analgesia in the management of post-operative pain. 4.3 CONTRAINDICATIONS Do not use in cats. Do not use in pregnant or lactating bitches. Do not use in dogs less than 4 months of age. Do not use in cases of hypersensitivity to the active substance or to any of the excipients. Health Products Regulatory Authority 02 November 2018 CRN000YDN Page 2 of 5 Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Refer to Sections 4.3 and 4.5. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals Use in aged dogs may involve additional risk. If such a use cannot be avoided, dogs may require careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated. See section 4.8. The tablets are flavoured. In order to avoid any accidental ingestion, st Izlasiet visu dokumentu